Diagnosis of COVID-19 by analysis of breath with gas chromatography-ion mobility spectrometry - a feasibility study.
Aldehydes
Breath-analysis
Breath-testing
Covid-19 diagnostics
GC-IMS
Gas chromatography-ion mobility spectrometry
Ketones
Methanol
Multi-variate analysis
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
15
08
2020
revised:
09
10
2020
accepted:
09
10
2020
pubmed:
3
11
2020
medline:
3
11
2020
entrez:
2
11
2020
Statut:
ppublish
Résumé
There is an urgent need to rapidly distinguish COVID-19 from other respiratory conditions, including influenza, at first-presentation. Point-of-care tests not requiring laboratory- support will speed diagnosis and protect health-care staff. We studied the feasibility of using breath-analysis to distinguish these conditions with near-patient gas chromatography-ion mobility spectrometry (GC-IMS). Independent observational prevalence studies at Edinburgh, UK, and Dortmund, Germany, recruited adult patients with possible COVID-19 at hospital presentation. Participants gave a single breath-sample for VOC analysis by GC-IMS. COVID-19 infection was identified by transcription polymerase chain reaction (RT- qPCR) of oral/nasal swabs together with clinical-review. Following correction for environmental contaminants, potential COVID-19 breath-biomarkers were identified by multi-variate analysis and comparison to GC-IMS databases. A COVID-19 breath-score based on the relative abundance of a panel of volatile organic compounds was proposed and tested against the cohort data. Ninety-eight patients were recruited, of whom 21/33 (63.6%) and 10/65 (15.4%) had COVID-19 in Edinburgh and Dortmund, respectively. Other diagnoses included asthma, COPD, bacterial pneumonia, and cardiac conditions. Multivariate analysis identified aldehydes (ethanal, octanal), ketones (acetone, butanone), and methanol that discriminated COVID-19 from other conditions. An unidentified-feature with significant predictive power for severity/death was isolated in Edinburgh, while heptanal was identified in Dortmund. Differentiation of patients with definite diagnosis (25 and 65) of COVID-19 from non-COVID-19 was possible with 80% and 81.5% accuracy in Edinburgh and Dortmund respectively (sensitivity/specificity 82.4%/75%; area-under-the-receiver- operator-characteristic [AUROC] 0.87 95% CI 0.67 to 1) and Dortmund (sensitivity / specificity 90%/80%; AUROC 0.91 95% CI 0.87 to 1). These two studies independently indicate that patients with COVID-19 can be rapidly distinguished from patients with other conditions at first healthcare contact. The identity of the marker compounds is consistent with COVID-19 derangement of breath-biochemistry by ketosis, gastrointestinal effects, and inflammatory processes. Development and validation of this approach may allow rapid diagnosis of COVID-19 in the coming endemic flu seasons. MR was supported by an NHS Research Scotland Career Researcher Clinician award. DMR was supported by the University of Edinburgh ref COV_29.
Sections du résumé
BACKGROUND
BACKGROUND
There is an urgent need to rapidly distinguish COVID-19 from other respiratory conditions, including influenza, at first-presentation. Point-of-care tests not requiring laboratory- support will speed diagnosis and protect health-care staff. We studied the feasibility of using breath-analysis to distinguish these conditions with near-patient gas chromatography-ion mobility spectrometry (GC-IMS).
METHODS
METHODS
Independent observational prevalence studies at Edinburgh, UK, and Dortmund, Germany, recruited adult patients with possible COVID-19 at hospital presentation. Participants gave a single breath-sample for VOC analysis by GC-IMS. COVID-19 infection was identified by transcription polymerase chain reaction (RT- qPCR) of oral/nasal swabs together with clinical-review. Following correction for environmental contaminants, potential COVID-19 breath-biomarkers were identified by multi-variate analysis and comparison to GC-IMS databases. A COVID-19 breath-score based on the relative abundance of a panel of volatile organic compounds was proposed and tested against the cohort data.
FINDINGS
RESULTS
Ninety-eight patients were recruited, of whom 21/33 (63.6%) and 10/65 (15.4%) had COVID-19 in Edinburgh and Dortmund, respectively. Other diagnoses included asthma, COPD, bacterial pneumonia, and cardiac conditions. Multivariate analysis identified aldehydes (ethanal, octanal), ketones (acetone, butanone), and methanol that discriminated COVID-19 from other conditions. An unidentified-feature with significant predictive power for severity/death was isolated in Edinburgh, while heptanal was identified in Dortmund. Differentiation of patients with definite diagnosis (25 and 65) of COVID-19 from non-COVID-19 was possible with 80% and 81.5% accuracy in Edinburgh and Dortmund respectively (sensitivity/specificity 82.4%/75%; area-under-the-receiver- operator-characteristic [AUROC] 0.87 95% CI 0.67 to 1) and Dortmund (sensitivity / specificity 90%/80%; AUROC 0.91 95% CI 0.87 to 1).
INTERPRETATION
CONCLUSIONS
These two studies independently indicate that patients with COVID-19 can be rapidly distinguished from patients with other conditions at first healthcare contact. The identity of the marker compounds is consistent with COVID-19 derangement of breath-biochemistry by ketosis, gastrointestinal effects, and inflammatory processes. Development and validation of this approach may allow rapid diagnosis of COVID-19 in the coming endemic flu seasons.
FUNDING
BACKGROUND
MR was supported by an NHS Research Scotland Career Researcher Clinician award. DMR was supported by the University of Edinburgh ref COV_29.
Identifiants
pubmed: 33134902
doi: 10.1016/j.eclinm.2020.100609
pii: S2589-5370(20)30353-9
pmc: PMC7585499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100609Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
DMR and CLPT report a grant from University of Edinburgh. TW reports personal fees from G.A.S. Gesellschaft für analytische Sensorsysteme mbH, outside the submitted work; In addition, Dr. Wortelmann has a patent PCT/EP2014/075236 pending.Dr. Wortelmann reports personal fees from G.A.S. Gesellschaft für analytische Sensorsysteme mbH, outside the submitted work; In addition, Dr. Wortelmann has a patent PCT/EP2014/075236 pending
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Chromatogr A. 2014 Apr 18;1338:136-48
pubmed: 24630058
BMJ. 2020 May 12;369:m1808
pubmed: 32398230
J Breath Res. 2020 Jul 21;14(4):041001
pubmed: 32531777
Diabetes Obes Metab. 2020 Oct;22(10):1935-1941
pubmed: 32314455
Eur Respir J. 2014 Jul;44(1):188-97
pubmed: 24743964
J Breath Res. 2021 Feb 12;:
pubmed: 33578396
J Med Virol. 2020 Jun;92(6):538-539
pubmed: 32096564
Physiol Rev. 2015 Apr;95(2):603-44
pubmed: 25834233
J Breath Res. 2020 May 27;14(3):034001
pubmed: 32163929
Gigascience. 2013 Oct 16;2(1):13
pubmed: 24131531
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Anal Bioanal Chem. 2019 Sep;411(24):6435-6447
pubmed: 31367803
Lancet. 2020 May 2;395(10234):1420-1421
pubmed: 32325027
J Proteome Res. 2012 Jun 1;11(6):3344-57
pubmed: 22574726
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Sci Rep. 2018 Oct 5;8(1):14857
pubmed: 30291257
BMJ Open. 2019 Mar 8;9(3):e025486
pubmed: 30852546
Nat Rev Rheumatol. 2020 Aug;16(8):413-414
pubmed: 32499548
Sci Rep. 2019 Dec 11;9(1):18894
pubmed: 31827195
Ann Transl Med. 2018 Jan;6(2):33
pubmed: 29430450